Moderna(NASDAQ:MRNA) reported Q4 2022 earnings of $3.61 per diluted share,
Analysts polled by Capital IQ expected $4.75.
Revenue for the quarter ended Dec. 31 was $4.86 billion, down from $6.94 billion a year earlier.
Analysts surveyed by Capital IQ expected $5.02 billion.